Vaccines
24 October 2016
Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed20 October 2016
Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection19 October 2016
Canadian Ebola vaccine enters new trial phase17 October 2016
First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients13 October 2016
Immunovaccine Announces Positive Phase 1 Topline Data for DepoVax(TM)-based Respiratory Syncytial Virus Vaccine Candidate11 October 2016
Positive Preclinical Data for Immunovaccine’s DepoVax(TM)-based Malarial Vaccine Presented at 2016 World Vaccine Congress Europe10 October 2016
Allergy Therapeutics presents enhanced efficacy data in a malaria vaccine model with its novel adjuvant system29 September 2016
Genocea’s Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial28 September 2016
Immune Design Announces Advancement of First GLAAS™-based Allergy Program into Clinical Development26 September 2016
Vical Announces Initiation of a Phase 2 Trial of Its HSV-2 Therapeutic DNA Vaccine for Genital Herpes26 September 2016
BARDA Grants $43.2 million USD to Sanofi Pasteur for Zika22 September 2016
ASIT Biotech Announces the Initiation of a Phase 2a Clinical Study of Its Second Product Candidate hdm-ASIT+TM for House Dust Mite Rhinitis20 September 2016
VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of Its Preventative Cytomegalovirus Vaccine Candidate19 September 2016
Vical and Astellas Announce Topline Results from a Phase 2 Study of Investigational Cytomegalovirus (CMV) Vaccine (ASP0113) in Kidney Transplant Patients16 September 2016
Novavax Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults13 September 2016
Prokarium to Develop First Vaccine to Protect Against Sexually Transmitted and Insect-Borne Zika Infections7 September 2016
Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003)News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports